Extracting pharmacological effects from the above information

This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacteria than the first-generation cephalosporins; it has good antibacterial activity against Escherichia coli, Klebsiella pneumoniae, etc., and has satisfactory activity against Haemophilus influenzae and gonococci, including beta-lactamase-producing strains; it is effective against most Gram-positive cocci, but faecal streptococci, methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis are resistant to it; its activity against anaerobic bacteria has not been fully studied, and Bacteroides fragilis is resistant; this product is stable to type I beta-lactamase and can be slowly hydrolyzed by some beta-lactamases.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria, and has antibacterial activity against most bacteria of the Enterobacteriaceae family, penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella, Pseudomonas aeruginosa, etc. It has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial effects on Chlamydia trachomatis, Mycoplasma, and Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibits DNA synthesis and replication, and causes bacterial death.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often also has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. It has poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

Pharmacological action: This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing influenza bacilli and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus aureus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It has good antimicrobial activity against Chlamydia trachomatis, Mycoplasma, Legionella, and also has antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication and causing bacterial death. Toxicological studies: Carcinogenicity and mutagenicity: Eight in vitro mutagenicity tests have been conducted on ciprofloxacin, and two of the results were positive (rat hepatocyte DNA repair test and mouse lymphoma cell reverse mutation test). However, the in vivo tests of rat hepatocyte DNA repair test, micronucleus test (mice), and dominant lethal test (mice) were all negative. Long-term in vivo carcinogenicity tests on rats and mice have been completed. After daily oral administration for 2 consecutive years, these animals did not show any carcinogenic and tumorigenic effects of ciprofloxacin. Reproductive toxicity: Reproductive studies using rats and mice taking 6 times the usual daily dose of the drug for humans have not found that ciprofloxacin is harmful to the fetus or causes fertility impairment. When ciprofloxacin is used in rabbits (30 and 100 mg/kg orally), gastrointestinal disorders occur, leading to weight loss and increased abortion in female rabbits. However, no teratogenic effects were observed at both doses. No maternal toxicity, embryotoxicity, or teratogenicity was observed after intravenous administration of up to 20 mg/kg. However, there are no adequate, well-controlled studies in pregnant women. Ciprofloxacin should be used in pregnant women only if the potential benefit outweighs the potential risk to the fetus.

This product is a formyl derivative of tetrahydrofolate, mainly used for the rescue of high-dose methotrexate and other folic acid antagonists. It can be converted into tetrahydrofolate by tetrahydrofolate reductase, which can limit the damage of methotrexate to normal cells and reverse the reaction of methotrexate to bone marrow and gastrointestinal mucosa, but it has no obvious effect on the neurotoxicity caused by methotrexate.